Details
Stereochemistry | ACHIRAL |
Molecular Formula | Tl |
Molecular Weight | 200.9708 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 1 |
SHOW SMILES / InChI
SMILES
[201Tl+]
InChI
InChIKey=ZLUSCZLCHQSJRU-OIOBTWANSA-N
InChI=1S/Tl/q+1/i1-3
Thallous chloride (also known as Thallium(I) chloride) is a chemical compound with the formula TlCl. Thallous Chloride Tl 201 Injection is a diagnostic radiopharmaceutical indicated for:
Myocardial perfusion imaging with planar scintigraphy or single-photon emission computed tomography (SPECT) for the diagnosis of coronary artery disease by localization of:
Non-reversible defects (myocardial infarction) which may have prognostic value regarding survival.
Reversible defects (myocardial ischemia) when used in conjunction with exercise or pharmacologic stress.
Localization of sites of parathyroid hyperactivity pre- and post-operatively in patients with elevated serum calcium and parathyroid hormone levels.
Originator
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Diagnostic | THALLOUS CHLORIDE TL 201 Approved UseThallous Chloride TI 201 Injection may be useful in myocardial perfusion imaging using either planar or SPECT (Single Photon Computed
Tomography) techniques for the diagnosis and localization of myocardial infarction. It may also have prognostic value regarding survival, when used in the clinically stable patient following the onset of symptoms of an acute myocardial infarction, to assess the site and size of the perfusion defect. Thallous Chloride TI 201 Injection may also be useful in conjunction with exercise stress testing as an adjunct in the diagnosis of ischemic heart disease (atherosclerotic coronary artery disease). It is usually not possible to differentiate recent from old myocardial infarction, or to differentiate between recent myocardial infarction and ischemia. Thallous Chloride TI 201 Injection is indicated also for the localization of sites of parathyroid hyperactivity in patients with elevated serum calcium and parathyroid hormone levels. It may also be useful in pre-operative screening to localize extrathyroidal and mediastinal sites of parathyroid hyperactivity and for postsurgical
reexamination. Thallous Chloride Tl 201 Injection has not been adequately demonstrated to be effective for the localization of normal parathyroid glands. Launch Date1977 |
|||
Diagnostic | THALLOUS CHLORIDE TL 201 Approved UseThallous Chloride TI 201 Injection may be useful in myocardial perfusion imaging using either planar or SPECT (Single Photon Computed
Tomography) techniques for the diagnosis and localization of myocardial infarction. It may also have prognostic value regarding survival, when used in the clinically stable patient following the onset of symptoms of an acute myocardial infarction, to assess the site and size of the perfusion defect. Thallous Chloride TI 201 Injection may also be useful in conjunction with exercise stress testing as an adjunct in the diagnosis of ischemic heart disease (atherosclerotic coronary artery disease). It is usually not possible to differentiate recent from old myocardial infarction, or to differentiate between recent myocardial infarction and ischemia. Thallous Chloride TI 201 Injection is indicated also for the localization of sites of parathyroid hyperactivity in patients with elevated serum calcium and parathyroid hormone levels. It may also be useful in pre-operative screening to localize extrathyroidal and mediastinal sites of parathyroid hyperactivity and for postsurgical
reexamination. Thallous Chloride Tl 201 Injection has not been adequately demonstrated to be effective for the localization of normal parathyroid glands. Launch Date1977 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/thallous-chloride.html
Recommended Dose
Myocardial perfusion
Planar scintigraphy: 37 to 74 MBq (1 to 2 mCi) administered intravenously
SPECT: 74 to 111 MBq (2 to 3 mCi) administered intravenously
Parathyroid hyperactivity localization
Planar or SPECT: 75 to 130 MBq (2 to 3.5 mCi) administered intravenously
Route of Administration:
Intravenous
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000177914
Created by
admin on Fri Dec 15 17:47:15 GMT 2023 , Edited by admin on Fri Dec 15 17:47:15 GMT 2023
|
||
|
NDF-RT |
N0000000205
Created by
admin on Fri Dec 15 17:47:15 GMT 2023 , Edited by admin on Fri Dec 15 17:47:15 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1546370
Created by
admin on Fri Dec 15 17:47:15 GMT 2023 , Edited by admin on Fri Dec 15 17:47:15 GMT 2023
|
PRIMARY | |||
|
4877X14G4C
Created by
admin on Fri Dec 15 17:47:15 GMT 2023 , Edited by admin on Fri Dec 15 17:47:15 GMT 2023
|
PRIMARY | |||
|
10130399
Created by
admin on Fri Dec 15 17:47:15 GMT 2023 , Edited by admin on Fri Dec 15 17:47:15 GMT 2023
|
PRIMARY | |||
|
4877X14G4C
Created by
admin on Fri Dec 15 17:47:15 GMT 2023 , Edited by admin on Fri Dec 15 17:47:15 GMT 2023
|
PRIMARY | |||
|
1546430
Created by
admin on Fri Dec 15 17:47:15 GMT 2023 , Edited by admin on Fri Dec 15 17:47:15 GMT 2023
|
ALTERNATIVE | |||
|
DB14576
Created by
admin on Fri Dec 15 17:47:15 GMT 2023 , Edited by admin on Fri Dec 15 17:47:15 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)